Dr. Berkay Yeşilyurt

Doctor and researcher Ankara Bilkent Şehir Hastanesi Ankara
Carcinoma, Renal CellKidney NeoplasmsBiliary Tract Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Renal Cell 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Kidney Neoplasms 2 publications
  • Biliary Tract Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Renal CellExtracted from 2 publications · Model version —From source
  • Publications14 publicationsORCID, Europe PMC, OpenAlexFrom source
  • ORCID0000-0003-0130-7111ORCIDFrom source
  • Last synchronised7 November 2026 00:02https://ankarasehir.saglik.gov.tr/TR-331078/tibbi-onkoloji-klinigi-doktorlarimiz.html#berkay-yesilyurtsaglik.gov.tr

Scientific work

Publications on Carcinoma, Renal Cell

14 publications

  1. Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

    Cancers, 2026

    DOI 10.3390/cancers18030394 PMID 41681877 1 citation (Europe PMC) Open-access full textSource: ORCID

  2. Prognostic Value of the Lung Immune Prognostic Index in Metastatic Renal Cell Carcinoma Treated With Second-Line Immunotherapy

    International journal of urology : official journal of the Japanese Urological Association, 2026

    DOI 10.1111/iju.70619 PMID 42655932 Open-access full textSource: Europe PMC

  3. Long-term Outcomes and Prognostic Factors in Chordoma: A 20-year Single-center Experience

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-11-6 Open-access full textSource: OpenAlex

  4. Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma

    Future oncology (London, England), 2026

    DOI 10.1080/14796694.2026.2732589 PMID 42730632 Source: Europe PMC

  5. Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102653 PMID 42700745 Source: OpenAlex

  6. Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62050992 PMID 42195245 Open-access full textSource: ORCID

  7. Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)

    JCO global oncology, 2026

    DOI 10.1200/go-25-00655 PMID 41886718 Open-access full textSource: Europe PMC

  8. Impact of radiologically identified embryological origin on recurrence patterns and survival in resectable pancreatic head adenocarcinoma.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.4228 Source: OpenAlex

  9. Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study ( TOG / GI ‐ SAFRADJU ‐2501)

    International Journal of Cancer, 2026

    DOI 10.1002/ijc.70623 PMID 42372083 Open-access full textSource: OpenAlex

  10. HALP–GRIms Synergy Offers Superior Prognostic and Predictive Precision in Advanced Pancreatic Ductal Adenocarcinoma

    Research Square, 2025

    DOI 10.21203/rs.3.rs-7277845/v1 Open-access full textSource: OpenAlex

View all 14 publications